医学
急性播散性脑脊髓炎
视神经炎
多发性硬化
横贯性脊髓炎
扩大残疾状况量表
儿科
视神经脊髓炎
髓鞘少突胶质细胞糖蛋白
内科学
脑炎
外科
免疫学
病毒
实验性自身免疫性脑脊髓炎
作者
Itay Lotan,John J. Chen,Yael Hacohen,Omar Abdel‐Mannan,Sara Mariotto,Saif Huda,Emily Gibbons,Adi Wilf‐Yarkoni,Mark A. Hellmann,Hadas Stiebel‐Kalish,Amy Kunchok,Eoin P. Flanagan,Negar Molazadeh,Monique Anderson,Rebecca Salky,Gabriela Romanow,Patrick Schindler,Ankelien Duchow,Friedemann Paul,Michael Levy
标识
DOI:10.1177/13524585231184738
摘要
Background: The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown. Objective: The objective was to describe the outcomes of IVIG treatment for acute MOGAD attacks. Methods: A retrospective observational study involving seven tertiary neuroimmunology centers. Data collection included patients’ demographics, Expanded Disability Status Scale (EDSS), and visual acuity (VA) before the attack, at the nadir of the attack before IVIG treatment, and at follow-up visits ⩾3 months after treatment. Results: Thirty-nine patients were included, of which 21 (53.8%) were female. The median age was 23 years (range 5–74 years), and the median disease duration was 4 months (range 0–93 months). The most common type of attack treated with IVIG was isolated optic neuritis (ON) (unilateral n = 14, bilateral n = 5, associated with transverse myelitis (TM), n = 1), followed by acute disseminated encephalomyelitis (ADEM) ( n = 8), multifocal ( n = 7), TM ( n = 3), brainstem ( n = 1), and other encephalitis ( n = 1). A significant improvement in both the EDSS and VA measures was observed at follow-up compared to the time of IVIG treatment initiation ( p < 0.0001 for both outcome measures). Conclusion: IVIG may be an effective treatment option for acute MOGAD attacks. Further prospective studies are warranted to validate our results.
科研通智能强力驱动
Strongly Powered by AbleSci AI